FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068977368> ?p ?o ?g. }

• W2068977368 endingPage "1041" @default.
• W2068977368 startingPage "1033" @default.
• W2068977368 abstract "Abstract BACKGROUND Little is known regarding long‐term prognosis among patients with Philadelphia chromosome (Ph)‐positive chronic myelogenous leukemia (CML) who achieve a complete cytogenetic response (0% Ph‐positive cells) after treatment with interferon‐α. METHODS The authors analyzed 512 patients with Ph‐positive, early chronic‐phase CML who were treated with interferon‐based therapies between 1981–1995 for the incidence and durability of complete cytogenetic response, and in relation to long‐term prognosis. RESULTS One hundred forty patients (27%) achieved a complete cytogenetic response. Their 10‐year survival rate was 78%. At the time of last follow‐up, 44 patients (31%, 9% of the total) were alive, 21 in first and 23 in second durable complete cytogenetic response (median, 127 months; range, 88–191 months); 39 patients had not received any therapy for a median of 50 months (range, 11–139 months). Analysis by reverse transcriptase‐polymerase chain reaction in 78 patients during complete cytogenetic response showed 46 who had achieved at least 1 complete molecular response. Five of these 78 patients had died by the time of last follow‐up, but only 2 had died of disease‐specific causes. Recurrence rates were significantly lower and cytogenetic response durations were significantly longer among patients who achieved at least one complete molecular response. CONCLUSIONS Achieving a complete cytogenetic or molecular response after therapy with interferon‐α appears to be associated with excellent long‐term prognosis. Approximately 10% of patients reportedly can achieve durable complete cytogenetic response, with or without continuation of interferon. This finding emphasizes the potential of long‐term event‐free survival in CML patients outside the context of allogeneic stem cell transplantation, which may be improved with new therapies such as imatinib mesylate. Cancer 2003;97:1033–41. © 2003 American Cancer Society. DOI 10.1002/cncr.11223" @default.
• W2068977368 created "2016-06-24" @default.
• W2068977368 creator A5006104041 @default.
• W2068977368 creator A5011529063 @default.
• W2068977368 creator A5015140142 @default.
• W2068977368 creator A5027575595 @default.
• W2068977368 creator A5028070547 @default.
• W2068977368 creator A5028845635 @default.
• W2068977368 creator A5038302480 @default.
• W2068977368 creator A5046097970 @default.
• W2068977368 creator A5059555096 @default.
• W2068977368 creator A5061285204 @default.
• W2068977368 creator A5085521139 @default.
• W2068977368 creator A5089428686 @default.
• W2068977368 creator A5090435894 @default.
• W2068977368 date "2003-02-03" @default.
• W2068977368 modified "2023-10-18" @default.
• W2068977368 title "Complete cytogenetic and molecular responses to interferon‐α‐based therapy for chronic myelogenous leukemia are associated with excellent long‐term prognosis" @default.
• W2068977368 cites W1498708301 @default.
• W2068977368 cites W188630774 @default.
• W2068977368 cites W2006518962 @default.
• W2068977368 cites W2011474502 @default.
• W2068977368 cites W2038990138 @default.
• W2068977368 cites W2058190985 @default.
• W2068977368 cites W2058558811 @default.
• W2068977368 cites W2066790912 @default.
• W2068977368 cites W2067635683 @default.
• W2068977368 cites W2076372887 @default.
• W2068977368 cites W2080048865 @default.
• W2068977368 cites W2097255369 @default.
• W2068977368 cites W2103072940 @default.
• W2068977368 cites W2122797075 @default.
• W2068977368 cites W2128738046 @default.
• W2068977368 cites W2142969636 @default.
• W2068977368 cites W2171722798 @default.
• W2068977368 cites W2329648702 @default.
• W2068977368 cites W2337277825 @default.
• W2068977368 cites W2337803710 @default.
• W2068977368 cites W2402092920 @default.
• W2068977368 cites W2508058084 @default.
• W2068977368 cites W2587781815 @default.
• W2068977368 cites W38386901 @default.
• W2068977368 cites W4238920715 @default.
• W2068977368 cites W4247887669 @default.
• W2068977368 cites W4248644843 @default.
• W2068977368 doi "https://doi.org/10.1002/cncr.11223" @default.
• W2068977368 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12569603" @default.
• W2068977368 hasPublicationYear "2003" @default.
• W2068977368 type Work @default.
• W2068977368 sameAs 2068977368 @default.
• W2068977368 citedByCount "209" @default.
• W2068977368 countsByYear W20689773682012 @default.
• W2068977368 countsByYear W20689773682013 @default.
• W2068977368 countsByYear W20689773682014 @default.
• W2068977368 countsByYear W20689773682015 @default.
• W2068977368 countsByYear W20689773682016 @default.
• W2068977368 countsByYear W20689773682017 @default.
• W2068977368 countsByYear W20689773682018 @default.
• W2068977368 countsByYear W20689773682019 @default.
• W2068977368 countsByYear W20689773682020 @default.
• W2068977368 countsByYear W20689773682021 @default.
• W2068977368 countsByYear W20689773682022 @default.
• W2068977368 countsByYear W20689773682023 @default.
• W2068977368 crossrefType "journal-article" @default.
• W2068977368 hasAuthorship W2068977368A5006104041 @default.
• W2068977368 hasAuthorship W2068977368A5011529063 @default.
• W2068977368 hasAuthorship W2068977368A5015140142 @default.
• W2068977368 hasAuthorship W2068977368A5027575595 @default.
• W2068977368 hasAuthorship W2068977368A5028070547 @default.
• W2068977368 hasAuthorship W2068977368A5028845635 @default.
• W2068977368 hasAuthorship W2068977368A5038302480 @default.
• W2068977368 hasAuthorship W2068977368A5046097970 @default.
• W2068977368 hasAuthorship W2068977368A5059555096 @default.
• W2068977368 hasAuthorship W2068977368A5061285204 @default.
• W2068977368 hasAuthorship W2068977368A5085521139 @default.
• W2068977368 hasAuthorship W2068977368A5089428686 @default.
• W2068977368 hasAuthorship W2068977368A5090435894 @default.
• W2068977368 hasConcept C104317684 @default.
• W2068977368 hasConcept C126322002 @default.
• W2068977368 hasConcept C138626823 @default.
• W2068977368 hasConcept C174475383 @default.
• W2068977368 hasConcept C203014093 @default.
• W2068977368 hasConcept C2776178377 @default.
• W2068977368 hasConcept C2776694085 @default.
• W2068977368 hasConcept C2776960273 @default.
• W2068977368 hasConcept C2778461978 @default.
• W2068977368 hasConcept C2778904597 @default.
• W2068977368 hasConcept C3019096185 @default.
• W2068977368 hasConcept C30481170 @default.
• W2068977368 hasConcept C54355233 @default.
• W2068977368 hasConcept C71924100 @default.
• W2068977368 hasConcept C86803240 @default.
• W2068977368 hasConcept C90924648 @default.
• W2068977368 hasConceptScore W2068977368C104317684 @default.
• W2068977368 hasConceptScore W2068977368C126322002 @default.
• W2068977368 hasConceptScore W2068977368C138626823 @default.
• W2068977368 hasConceptScore W2068977368C174475383 @default.
• W2068977368 hasConceptScore W2068977368C203014093 @default.

• next